AU2012252165A1 - Methods of modulating micrornas in the treatment of pulmonary arterial hypertension - Google Patents

Methods of modulating micrornas in the treatment of pulmonary arterial hypertension Download PDF

Info

Publication number
AU2012252165A1
AU2012252165A1 AU2012252165A AU2012252165A AU2012252165A1 AU 2012252165 A1 AU2012252165 A1 AU 2012252165A1 AU 2012252165 A AU2012252165 A AU 2012252165A AU 2012252165 A AU2012252165 A AU 2012252165A AU 2012252165 A1 AU2012252165 A1 AU 2012252165A1
Authority
AU
Australia
Prior art keywords
mir
inhibitor
sequence
antisense oligonucleotide
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012252165A
Other languages
English (en)
Inventor
Andrew Baker
Margaret MACLEAN
Nicholas Morrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Cambridge Enterprise Ltd
Original Assignee
University of Glasgow
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Cambridge Enterprise Ltd filed Critical University of Glasgow
Publication of AU2012252165A1 publication Critical patent/AU2012252165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012252165A 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension Abandoned AU2012252165A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161484091P 2011-05-09 2011-05-09
US61/484,091 2011-05-09
US201261605376P 2012-03-01 2012-03-01
US61/605,376 2012-03-01
PCT/GB2012/051018 WO2012153135A1 (en) 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
AU2012252165A1 true AU2012252165A1 (en) 2013-03-21

Family

ID=46178572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012252165A Abandoned AU2012252165A1 (en) 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Country Status (11)

Country Link
US (1) US9267134B2 (enExample)
EP (1) EP2707485B1 (enExample)
JP (1) JP6049700B2 (enExample)
KR (1) KR20140037868A (enExample)
CN (1) CN103814131A (enExample)
AU (1) AU2012252165A1 (enExample)
BR (1) BR112013029016A2 (enExample)
CA (1) CA2835568A1 (enExample)
CO (1) CO6870004A2 (enExample)
SG (1) SG194901A1 (enExample)
WO (1) WO2012153135A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
WO2015082896A1 (en) * 2013-12-02 2015-06-11 The University Court Of The University Of Glasgow Materials and methods for treatment of pulmonary arterial hypertension
CA2956256A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
BR112017014914B1 (pt) * 2015-01-13 2023-11-14 Vivus, Inc Uso de uma combinação de tacrolimus e um segundo agente ativo eficaz no tratamento ou prevenção da hipertensão pulmonar
CN110088278B (zh) * 2016-10-31 2023-08-11 e-NA生物科技公司 双链核酸分子及其用途
CN115175685B (zh) * 2019-12-09 2024-12-13 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
JP2024504679A (ja) * 2021-01-18 2024-02-01 リジェン イノファーム インコーポレイテッド ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物
CN113332306A (zh) * 2021-04-28 2021-09-03 武汉华纪元生物技术开发有限公司 用于治疗肺动脉高血压的microRNA-30a抑制剂及其应用
GB202215974D0 (en) * 2022-10-28 2022-12-14 Imperial College Innovations Ltd Microrna panels for pulmonary hypertension

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
ATE211741T1 (de) 1996-05-31 2002-01-15 C & C Res Lab Aromatische amidinderivate als selektive thrombininhibitoren
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
SI20474A (sl) 1998-05-26 2001-08-31 Icn Pharmaceuticals, Inc. Novi nukleozidi, ki imajo bicikličen sladkorni del
EP1117398A2 (en) 1998-09-28 2001-07-25 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
BRPI0508073A (pt) 2004-02-26 2007-07-17 Kardia Pty Ltd V método e aparelho para isolar substancialmente circulação cardìaca da circulação sistêmica aparelho para perfundir o coração com um agente terapêutico, cateter de obstrução para obstruir fluxo entre um vaso principal e um ou mais vasos ramificados, método para administrar um agente terapêutico ao coração e estrutura de suporte percutaneamente administrável para manter patência do sinus coronário
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna
WO2009121031A1 (en) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US8735568B2 (en) 2009-03-09 2014-05-27 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
CN101843632B (zh) * 2009-03-24 2012-07-04 复旦大学附属华山医院 miR-145在制备治疗炎症药物中的应用
SG176716A1 (en) * 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
US20130005658A1 (en) * 2009-12-15 2013-01-03 Board Of Regents, The University Of Texas System Micro-rna regulation in ischemia and ischemia-reperfusion injury
CN102382824A (zh) * 2010-09-01 2012-03-21 中国科学院上海药物研究所 人miR-145反义核酸及其应用

Also Published As

Publication number Publication date
BR112013029016A2 (pt) 2017-01-17
EP2707485A1 (en) 2014-03-19
KR20140037868A (ko) 2014-03-27
WO2012153135A1 (en) 2012-11-15
SG194901A1 (en) 2013-12-30
JP6049700B2 (ja) 2016-12-21
CO6870004A2 (es) 2014-02-20
US9267134B2 (en) 2016-02-23
JP2014516027A (ja) 2014-07-07
CA2835568A1 (en) 2012-11-15
CN103814131A (zh) 2014-05-21
EP2707485B1 (en) 2016-12-14
US20140163086A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
US9267134B2 (en) Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension
AU2007334502B2 (en) Compositions and methods to treat muscular & cardiovascular disorders
JP6157852B2 (ja) 多繊毛上皮細胞における繊毛の機能不全に関連する疾患を治療するためのマイクロｒｎａの使用
AU2010210605B2 (en) Dual targeting of miR-208 and miR-499 in the treatment of cardiac disorders
US20120282326A1 (en) Compositions and methods related to mirna in diabetic conditions
EP2968396B1 (en) Locked nucleic acid inhibitor of mir-145 and uses thereof
EP2852669B1 (en) Therapeutic micro rna targets in chronic pulmonary diseases
WO2010129950A1 (en) Micro-rna that regulates cardiac remodeling
Samples A Role for miR-145 in Pulmonary Arterial Hypertension

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted